NCT06496568 2026-03-18A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab, and Inavolisib Plus Pembrolizumab in PIK3CA-Mutated CancersHoffmann-La RochePhase 1 Recruiting30 enrolled